Vyome Holdings (HIND) presented results from its preclinical studies investigating VT-1908 for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics. In a preclinical model of anterior uveitis, the most common form of uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score. The efficacy of VT-1908 was found to be similar to a clinically used steroid.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIND:
- Vyome Holdings appoints Richard Fahrner as CTO
- Vyome Holdings announces positive interim data from VT-1953 Phase 2 study
- Vyome Holdings Completes Merger with Vyome Therapeutics
- Vyome Holdings, Embryyo Technologies sign MoU for AI-enabled medical devices
- Vyome Holdings Amends Equity Distribution Agreement